论文部分内容阅读
目的:探讨香贝养荣汤加减辨治转移性乳腺癌(气血两虚)的近期疗效及对T淋巴细胞亚群和NK细胞的影响。方法:将90例转移性乳腺癌患者,根据入院先后顺序随机按数字表法分成观察组46例和对照组44例。对照组给予内分泌治疗,必要时加用化疗。观察组在对照组治疗的基础上加香贝养荣汤加减治疗。两组疗程直到疾病出现进展。进行气血两虚及兼证评分;进行功能状态Kupperman评分;记录疾病进展时间(TTP);采用乳腺癌患者生命质量测定量表(FACT-B)和KPS评分;检测T淋巴细胞亚群和自然杀伤细胞(NK)水平,记录不良反应。结果:观察组临床总有效率为54.35%,高于对照组的31.82%(P<0.05);对照组TTP(5.12±1.04)个月,观察组为(7.91±1.41)个月,观察组TTP长于对照组(P<0.05);治疗后观察组症状评分和Kupperman评分低于对照组,KPS评分高于对照组(P<0.01);治疗后观察组生理状况、社会家庭情况、情感情况、功能状况和附加关注5个维度评分均低于对照组(P<0.01);治疗后观察组CD3~+,CD4~+,CD4~+/CD8~+和NK水平上升,并高于同期对照组(P<0.01),CD8~+水平明显降低,并低于对照组(P<0.01);对照组化疗导致不良反应程度重于观察组(P<0.05)。结论:香贝养荣汤加减方辨治转移性乳腺癌内分泌治疗或(和)化疗的患者,能延长TTP,提高近期实体瘤疗效,能减轻症状、提高患者生活质量和提高免疫功能,并能减轻内分泌和化疗导致的不良反应。
Objective: To investigate the short-term effect of Xiangbian Yang Rong Decoction on differentiation and metastasis of metastatic breast cancer (Qi and blood deficiency) and its effect on T lymphocyte subsets and NK cells. Methods: Ninety patients with metastatic breast cancer were randomly divided into observation group (46 cases) and control group (44 cases) according to the order of admission. Control group given endocrine therapy, if necessary, plus chemotherapy. Observation group in the control group on the basis of plus Xiangbei Rongrong Decoction treatment. Two groups until the disease progress. The Kupperman score of functional status was recorded. The time to progression of disease (TTP) was recorded. The FACT-B and KPS scores of breast cancer patients were used to detect T lymphocyte subsets and natural Killer cell (NK) levels were recorded and adverse reactions recorded. Results: The total effective rate in the observation group was 54.35%, higher than that in the control group (31.82%, P <0.05). In the control group, the TTP (5.12 ± 1.04) months in the observation group was (7.91 ± 1.41) (P <0.05). After treatment, symptom score and Kupperman score of the observation group were lower than those of the control group, and KPS score was higher than that of the control group (P <0.01). After treatment, the physiological status, social family situation, emotional status and function (P <0.01). After treatment, the levels of CD3 +, CD4 +, CD4 + / CD8 + and NK in the observation group were significantly higher than those in the control group (P <0.01) (P <0.01). The levels of CD8 + in the control group were significantly lower than those in the control group (P <0.01). The degree of adverse reactions in the control group was higher than that in the observation group (P <0.05). Conclusion: Xiangbei Yangrun Decoction can treat patients with metastatic breast cancer endocrine therapy or (or) chemotherapy, prolong TTP, improve the curative effect of recent solid tumors, relieve symptoms, improve patient quality of life and improve immune function, and can Reduce the endocrine and chemotherapy-induced adverse reactions.